T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities
Authors
Keywords
-
Journal
CURRENT OPINION IN ONCOLOGY
Volume 34, Issue 5, Pages 552-558
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-07-26
DOI
10.1097/cco.0000000000000869
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment
- (2022) Allison M. Bock et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- BiTEs better than CAR T cells
- (2021) Marion Subklewe Blood Advances
- Emerging Immunotherapy for Acute Myeloid Leukemia
- (2021) Rikako Tabata et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches
- (2021) Hwai Wen Chang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- (2021) Paul Nathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors
- (2021) Brian Belmontes et al. Science Translational Medicine
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
- (2021) Golnaz Morad et al. CELL
- 867 TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation
- (2021) Kathryn Kwant et al. Journal for ImmunoTherapy of Cancer
- 571 IL-2 combination with ImmTAC overcomes CD163+ TAM-like M2 macrophage inhibition of ImmTAC-mediated T cell killing of tumor cells
- (2021) Rahul Khanolkar et al. Journal for ImmunoTherapy of Cancer
- CAR T cells: continuation in a revolution of immunotherapy
- (2020) Anurag K Singh et al. LANCET ONCOLOGY
- A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
- (2020) Dimitris Skokos et al. Science Translational Medicine
- T cell-engaging therapies — BiTEs and beyond
- (2020) Maria-Elisabeth Goebeler et al. Nature Reviews Clinical Oncology
- BCMA-targeted immunotherapy for multiple myeloma
- (2020) Bo Yu et al. Journal of Hematology & Oncology
- TriTACs, a novel class of T cell-engaging protein constructs designed for the treatment of solid tumors
- (2020) Richard J Austin et al. MOLECULAR CANCER THERAPEUTICS
- Cytokine Storm
- (2020) David C. Fajgenbaum et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response
- (2019) Patrick A. Baeuerle et al. Nature Communications
- The Therapeutic Potential of Nanobodies
- (2019) Ivana Jovčevska et al. BIODRUGS
- Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
- (2019) Karen A. Autio et al. CLINICAL CANCER RESEARCH
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
- (2018) Maxim Kebenko et al. OncoImmunology
- Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies
- (2018) Richard Burt et al. Human Vaccines & Immunotherapeutics
- Opportunities and challenges for TCR mimic antibodies in cancer therapy
- (2016) Aaron Y. Chang et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
- (2015) G. Zugmaier et al. BLOOD
- FDA Approval: Blinatumomab
- (2015) D. Przepiorka et al. CLINICAL CANCER RESEARCH
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- The Immunological Synapse
- (2014) M. L. Dustin Cancer Immunology Research
- Exploiting the curative potential of adoptive T-cell therapy for cancer
- (2013) Christian S. Hinrichs et al. IMMUNOLOGICAL REVIEWS
- Abstract 4841: Lysis of cancer cells by highly purified T regulatory cells engaged via an EpCAM/CD3-bispecific BiTE antibody
- (2012) Markus Münz et al. CANCER RESEARCH
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
- (2010) Ralf Lutterbuese et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
- (2009) Cornelia Haas et al. IMMUNOBIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started